Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13029-13040
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
Edward Price, Manuel Weinheimer, Alexey Rivkin, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5683-5698
Closed Access | Times Cited: 25
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Exploring the chemical space of orally bioavailable PROTACs
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 17
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies
Elisa Uliassi, María Laura Bolognesi, Andrea Milelli
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 3, pp. 654-672
Closed Access | Times Cited: 2
Degrader–Antibody Conjugates: Emerging New Modality
Ki Bum Hong, Hongchan An
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 140-148
Closed Access | Times Cited: 41
Biophysical and Computational Approaches to Study Ternary Complexes: A ‘Cooperative Relationship’ to Rationalize Targeted Protein Degradation
Jake A. Ward, Carles Perez‐Lopez, Cristina Mayor‐Ruiz
ChemBioChem (2023) Vol. 24, Iss. 10
Open Access | Times Cited: 33
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 31
Molecular chameleons in drug discovery
Vasanthanathan Poongavanam, Lianne H. E. Wieske, Stefan Peintner, et al.
Nature Reviews Chemistry (2023) Vol. 8, Iss. 1, pp. 45-60
Closed Access | Times Cited: 31
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Barmak Mostofian, Holli‐Joi Martin, Asghar M. Razavi, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 17, pp. 5408-5432
Open Access | Times Cited: 27
Predictive Modeling of PROTAC Cell Permeability with Machine Learning
Vasanthanathan Poongavanam, Florian Kölling, Anja Giese, et al.
ACS Omega (2023) Vol. 8, Iss. 6, pp. 5901-5916
Open Access | Times Cited: 22
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Structural and Physicochemical Features of Oral PROTACs
Markus Schade, James S. Scott, Thomas G. Hayhow, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13106-13116
Closed Access | Times Cited: 12
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Yufeng Xiao, Yaxia Yuan, Yi Liu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 8
Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
Toshihiko Tashima
Antibodies (2023) Vol. 12, Iss. 3, pp. 43-43
Open Access | Times Cited: 20
The most common linkers in bioactive molecules and their bioisosteric replacement network
Peter Ertl, Eva Altmann, Sophie Racine
Bioorganic & Medicinal Chemistry (2023) Vol. 81, pp. 117194-117194
Closed Access | Times Cited: 19
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy
Song Chen, Zhendong Chen, Lixue Lu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 255, pp. 115403-115403
Closed Access | Times Cited: 18
PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer’s Disease
Melissa Guardigni, Letizia Pruccoli, Alan Santini, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 11, pp. 1963-1970
Open Access | Times Cited: 18
Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs
Diego García Jiménez, Maura Vallaro, Matteo Rossi Sebastiano, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10681-10693
Open Access | Times Cited: 18
Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
Rebecca Stevens, Enrique Bendito-Moll, David Battersby, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15437-15452
Closed Access | Times Cited: 18
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Hongyi Zhao, Minhang Xin, San‐Qi Zhang
Drug Development Research (2023) Vol. 84, Iss. 2, pp. 337-394
Closed Access | Times Cited: 16
Reversible Assembly of Proteolysis Targeting Chimeras
Weijun Gui, Sarah F. Giardina, Madeline Balzarini, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 7, pp. 1582-1593
Closed Access | Times Cited: 16
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
IMHB-Mediated Chameleonicity in Drug Design: A Focus on Structurally Related PROTACs
Diego García Jiménez, Matteo Rossi Sebastiano, Maura Vallaro, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11421-11434
Closed Access | Times Cited: 6
Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs)
Hidetomo Yokoo, Mikihiko Naito, Yosuke Demizu
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 4, pp. 357-361
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top